Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy

Frontiers in Medicine

article

Alona A. Merkulova¹  Steven C. Mitchell¹  Sergei Merkulov²  Alisa S. Wolberg³  Marguerite Neerman-Arbez⁴  Alvin H. Schmaier¹ 

[1] Department of Medicine, Case Western Reserve University, United States;Department of Medicine, Cardiovascular Medicine, Case Western Reserve University, United States;Department of Pathology and Laboratory Medicine, University of North Carolina, United States;Department of Genetic Medicine and Development, University Medical Center Geneva;Division of Angiology and Haemostasis, University Hospital;Department of Medicine, University Hospitals Cleveland Medical Center, United States

关键词: dysfibrinogenemia;    everolimus;    CVID;    fibrin polymerization;    dysfibrinogenemia Krakow III;   

DOI  :  10.3389/fmed.2020.591546

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

A previously hemostatically asymptomatic patient with common variable hypogammaglobulinemia was given everolimus to prevent growth of her liver. Within several months, the patient developed a severe bleeding disorder. The bleeding was due to fibrin polymerization defect that upon sequencing was shown to be dysfibrinogenemia Krakow III. Elimination of the mTor inhibitor ameliorated the clinical bleeding state.

【 授权许可】

CC BY